Sanofi (NASDAQ: SNY - Get Free Report) saw some unusual options trading activity on Monday. Stock traders acquired 14,850 put options on the company. This is an increase of approximately 370% compared
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Sanofi (SNY) has announced an agreement to acquire Dynavax (DVAX) for $15.50 per share, valuing the deal at approximately $2.2 billion. This acquisition will en
Sanofi (SNY, Financials) stated on Wednesday that it would buy Dynavax Technologies for around $2.2 billion, or $15.50 per share in cash. This is a 39% premium
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult imm
Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.
Shares of Dynavax Technologies (DVAX) surged about 37% on early Wednesday after French drugmaker Sanofi (SNY) agreed to buy the U.S. vaccine company in a cash d
Shares of Dynavax Technologies jumped sharply in premarket trading on Wednesday after the US vaccine maker agreed to be acquired by French pharmaceutical group Sanofi in an all-cash deal valued at abo
Sanofi will buy vaccine maker Dynavax Technologies for $2.2 billion, or $15.50 a share, adding to its adult immunizations. Dynavax stock soared.
Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult immunization.
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price on December 23, 2025 EMERYVILLE, Calif. , Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE